A.I. BURNASYAN FMBC CLINICAL BULLETIN

ISSN 2782-6430 (print)

State Research Center −Burnasyan Federal Medical Biophysical
Center of Federal Medical Biological Agency

The journal is published in Russian.
Format – A4.
The periodicity of the journal is 4 times a year.

Issue №2 2025 год

more

A.I. Burnasyan  FMBC clinical bulletin. 2025 № 1

A.A. Voroshkevich1,2, T.A. Astrelina2, A.S. Samoilov2

Features of Treatment of Patients with Multiple Myeloma, Aggravated
by Adverse Cytogenetic Disorders (Literary Review)

1M.F. Vladimirsky Moscow Regional Scientific Research Clinical Institute, Russiа

2International Office, State Research Center – Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency, Moscow, Russiа

Contact person: Astrelina Tatyana Alekseevna: t_astrelina@mail.ru

 
Abstract
Multiple myeloma accounts for about 10% of hematological malignancies. Diagnosis requires the presence of ≥10% of clonal plasma cells in bone marrow punctate or plasmocytoma, confirmed by biopsy, as well as the presence of one or more criteria: CRAB syndrome (hypercalcemia, renal failure, anemia or lytic lesions of skeletal bones), the ratio of involved/uninvolved free light chains (SLC) in serum ≥100 (when provided that the involved SLC is ≥100 mg/l, and the monoclonal protein of urine is ≥200 mg/24 h). The presence of del(17p), t(4;14), t(14;16), t(14;20), 1q21+ or p53 mutation is considered a high-risk multiple myeloma. The presence of any two high-risk factors is considered double—hit myeloma; three or more high-risk factors are triple-hit myeloma. Despite recent advances in the treatment of patients with multiple myeloma (MM), a group of patients with high-risk diseases continues to show disappointing results of standard therapy. This review presents the features of the treatment of patients with multiple myeloma, burdened with adverse cytogenetic abnormalities.

Keywords: multiple myeloma, cytogenetic abnormalities, diagnosis, treatment, patients

For citation: Voroshkevich AA, Astrelina TA, Samoilov AS. Features of Treatment of Patients with Multiple Myeloma, Aggravated by Adverse Cytogenetic Disorders (Literary Review). A.I. Burnasyan Federal Medical Biophysical Center Clinical Bulletin. 2025.1:35-41. (In Russian) DOI: 10.33266/2782-6430-2025-1-35-41

 

REFERENCES

  1. Менделеева Л.П., Вотякова О.М., Рехтина И.Г. Множественная миелома: Российские клинические рекомендации по диагностике и лечению злокачественных лимфопролиферативных заболеваний / Под ред. И.В.Поддубной, В.Г.Савченко. М.: Ассоциация онкологов России, 2018. С. 213–241 [Mendeleyeva L.P., Votyakova O.M., Rekhtina I.G. Mnozhestvennaya Miyeloma = Multiple Myeloma: Russian Clinical Guidelines for the Diagnosis and Treatment of Malignant Lymphoproliferative Diseases. Ed. I.V.Poddubnaya, V.G.Savchenko. Moscow, Assotsiatsiya Onkologov Rossii Publ., 2018. 213-241 (In Russ.)].
  2. Rajkumar S.V. Multiple Myeloma: 2020 Update on Diagnosis, Risk-Stratification and Management. Am J Hematol. 2020 May;95;5:548–67. doi: 10.1002/ajh.25791.
  3. Barwick B.G., Gupta V.A., Vertino P.M., Boise L.H. Cell of Origin and Genetic Alterations in the Pathogenesis of Multiple Myeloma. Front Immunol. 2019 May 21;10:1121. doi: 10.3389/fimmu.2019.01121. PMID: 31231360; PMCID: PMC6558388.
  4. Kindred B., Shreffler DC. H-2 Dependence of Co-Оperation between T and B Cells in Vivo. J Immunol. 1972 Nov;109;5:940-3. PMID: 4538719.
  5. Mosmann T.R., Cherwinski H., Bond M.W., Giedlin M.A., Coffman R.L. Two Types of Murine Helper T Cell Clone. I. Definition According to Profiles of Lymphokine Activities and Secreted Proteins. J Immunol. 1986 Apr 1;136;7:2348-57. PMID: 2419430.
  6. Snapper C.M., Paul W.E. Interferon-Gamma and B Cell Stimulatory Factor-1 Reciprocally Regulate Ig Isotype Production. Science. 1987 May 22;236;4804:944-7. doi: 10.1126/science.3107127. PMID: 3107127.
  7. Muraguchi A., Hirano T., Tang B., Matsuda T., Horii Y., Nakajima K., Kishimoto T. The Essential Role of B Cell Stimulatory Factor 2 (BSF-2/IL-6) for the Terminal Differentiation of B Cells. J Exp Med. 1988 Feb 1;167;2:332-44. doi: 10.1084/jem.167.2.332. PMID: 3258006; PMCID: PMC2188837.
  8. Kawano M., Hirano T., Matsuda T., Taga T., Horii Y., Iwato K., Asaoku H., Tang B., Tanabe O., Tanaka H., et al. Autocrine Generation and Requirement of BSF-2/IL-6 for Human Multiple Myelomas. Nature. 1988 Mar 3;332;6159:83-5. doi: 10.1038/332083a0. PMID: 3258060.
  9. Robbiani D.F., Bothmer A., Callen E., Reina-San-Martin B., Dorsett Y., Difilippantonio S., Bolland D.J., Chen H.T., Corcoran A.E., Nussenzweig A., Nussenzweig M.C. AID is Required for the Chromosomal Breaks in C-Myc that Lead to C-Myc/IgH Translocations. Cell. 2008 Dec 12;135;6:1028-38. doi: 10.1016/j.cell.2008.09.062. PMID: 19070574; PMCID: PMC2713603.
  10. Palumbo A., Avet-Loiseau H., Oliva S., et al. Revised International Staging System for Multiple Myeloma: a Report from International Myeloma Working Group. J Clin Oncol. 2015;33;26:2863-2869.
  11. Cardona-Benavides I.J., de Ramón C., Gutiérrez N.C. Genetic Abnormalities in Multiple Myeloma: Prognostic and Therapeutic Implications. Cells. 2021 Feb 5;10;2:336. doi: 10.3390/cells10020336. PMID: 33562668; PMCID: PMC7914805.
  12. Kuehl W.M., Bergsagel P.L. Multiple Myeloma: Evolving Genetic Events and Host Interactions. Nat Rev Cancer. 2002 Mar;2;3:175-87. doi: 10.1038/nrc746. PMID: 11990854.
  13. Vincent Rajkumar S. Multiple Myeloma: 2022 Update on Diagnosis, Risk Stratification, and Management. Am J Hematol. 2022 Aug;97;8:1086-1107. doi: 10.1002/ajh.26590. Epub 2022 May 23.DOI: 10.1002/ajh.26590
  14. Fonseca R., Debes-Marun C.S., Picken E.B., Dewald G.W., Bryant S.C., Winkler J.M., Blood E., Oken M.M., Santana-Dávila R., González-Paz N., Kyle R.A., Gertz M.A., Dispenzieri A., Lacy M.Q., Greipp P.R. The Recurrent IgH Translocations are Highly Associated with Nonhyperdiploid Variant Multiple Myeloma. Blood. 2003 Oct 1;102;7:2562-7. doi: 10.1182/blood-2003-02-0493. Epub 2003 Jun 12. PMID: 12805059.
  15. Barwick B.G., Neri P., Bahlis N.J., Nooka A.K., Dhodapkar M.V., Jaye D.L., Hofmeister C.C., Kaufman J.L., Gupta V.A., Auclair D., Keats J.J., Lonial S., Vertino P.M., Boise L.H. Multiple Myeloma Immunoglobulin Lambda Translocations Portend Poor Prognosis. Nat Commun. 2019 Apr 23;10;1:1911. doi: 10.1038/s41467-019-09555-6. PMID: 31015454; PMCID: PMC6478743.
  16. Avet-Loiseau H., Li C., Magrangeas F., Gouraud W., Charbonnel C., Harousseau J.L., Attal M., Marit G., Mathiot C., Facon T., Moreau P., Anderson K.C., Campion L., Munshi N.C., Minvielle S. Prognostic Significance of Copy-Number Alterations in Multiple Myeloma. J Clin Oncol. 2009 Sep 20;27;27:4585-90. doi: 10.1200/JCO.2008.20.6136. Epub 2009 Aug 17. PMID: 19687334; PMCID: PMC2754906.
  17. Besse L., Sedlarikova L., Greslikova H., Kupska R., Almasi M., Penka M., Jelinek T., Pour L., Adam Z., Kuglik P., Krejci M., Hajek R., Sevcikova S. Cytogenetics in Multiple Myeloma Patients Progressing Into Extramedullary Disease. Eur J Haematol. 2016 Jul;97;1:93-100. doi: 10.1111/ejh.12688. Epub 2015 Oct 19. PMID: 26432667.
  18. Morgan G.J., Walker B.A., Davies F.E. The Genetic Architecture of Multiple Myeloma. Nat Rev Cancer. 2012 Apr 12;12;5:335–48. doi: 10.1038/nrc3257
  19. Kyle R.A., Durie B.G., Rajkumar S.V., Landgren O., Blade J., Merlini G., et al. Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering (Asymptomatic) Multiple Myeloma: IMWG Consensus Perspectives Risk Factors for Progression and Guidelines for Monitoring and Management. Leukemia. 2010 Jun;24;6:1121–7. doi: 10.1038/leu.2010.60.
  20. Bolli N., Maura F., Minvielle S., Gloznik D., Szalat R., Fullam A., Martincorena I., Dawson K.J., Samur M.K., Zamora J., Tarpey P., Davies H., Fulciniti M., Shammas M.A., Tai Y.T., Magrangeas F., Moreau P., Corradini P., Anderson K., Alexandrov L., Wedge D.C., Avet-Loiseau H., Campbell P., Munshi N. Genomic Patterns of Progression in Smoldering Multiple Myeloma. Nat Commun. 2018 Aug 22;9;1:3363. doi: 10.1038/s41467-018-05058-y. PMID: 30135448; PMCID: PMC6105687.
  21. Walker B.A., Boyle E.M., Wardell C.P., Murison A., Begum D.B., Dahir N.M., et al. Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients with Newly Diagnosed Myeloma. J Clin Oncol. 2015 Nov 20;33;33:3911–20. doi: 10.1200/JCO.2014.59.1503
  22. Walker B.A., Wardell C.P., Chiecchio L., Smith E.M., Boyd K.D., Neri A., et al. Aberrant Global Methylation Patterns Affect the Molecular Pathogenesis and Prognosis of Multiple Myeloma. Blood. 2011 Jan 13;117;2:553-62. doi: 10.1182/blood-2010-04-279539.
  23. Schmidt T.M., Fonseca R., Usmani S.Z. Chromosome 1q21 Abnormalities in Multiple Myeloma. Blood Cancer J. 2021 Apr 29;11;4:83. doi: 10.1038/s41408-021-00474-8
  24. Ribrag V., Avigan D.E., Green D.J., Wise-Draper T., Posada J.G., Vij R., et al. Phase 1b Trial of Pembrolizumab Monotherapy for Relapsed/Refractory Multiple Myeloma: KEYNOTE-013. Br J Haematol. 2019 Aug;186;3:e41-4. doi: 10.1111/bjh.15888.
  25. Jones J.R., Weinhold N., Ashby C., Walker B.A., Wardell C., Pawlyn C., et al. Clonal Evolution in Myeloma: the Impact of Maintenance Lenalidomide and Depth of Response on the Genetics and Sub-Clonal Structure of Relapsed Disease in Uniformly Treated Newly Diagnosed Patients. Haematologica. 2019 Jul;104;7:1440-50. doi: 10.3324/haematol.2018.202200
  26. McCarthy P.L., Holstein S.A., Petrucci M.T., Richardson P.G., Hulin C., Tosi P., et al. Lenalidomide Maintenance after Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: a Meta-Analysis. J Clin Oncol. 2017 Oct 10;35;29:3279–89. doi: 10.1200/JCO.2017.72.6679
  27. Boyle E.M., Deshpande S., Tytarenko R., Ashby C., Wang Y., Bauer M.A., et al. The Molecular Make up of Smoldering Myeloma Highlights the Evolutionary Pathways Leading to Multiple Myeloma. Nat Commun. 2021 Jan 12;12;1:293. doi: 10.1038/s41467-020-20524-2.
  28. Song W., van der Vliet H.J., Tai Y.T., Prabhala R., Wang R., Podar K., et al. Generation of Antitumor Invariant Natural Killer T Cell Lines in Multiple Myeloma and Promotion of their Functions Via Lenalidomide: a Strategy for Immunotherapy. Clin Cancer Res. 2008 Nov 1;14;21:6955–62. doi: 10.1158/1078-0432.CCR-07-5290.
  29. 29.Ribrag V, Avigan DE, Green DJ, Wise-Draper T, Posada JG, Vij R, et al. Phase 1b Trial of Pembrolizumab Monotherapy for Relapsed/Refractory Multiple Myeloma: KEYNOTE-013. Br J Haematol. 2019 Aug;186((3)):e41–4. doi: 10.1111/bjh.15888.
  30. Usmani S.Z., Hoering A., Ailawadhi S., Sexton R., Lipe B., Hita S.F., et al. Bortezomib, Lenalidomide, and Dexamethasone with or without Elotuzumab in Patients with Untreated, High-Risk Multiple Myeloma (SWOG-1211): Primary Analysis of a Randomised, Phase 2 Trial. Lancet Haematol. 2021;8;1:e45–e54. doi: 10.1016/S2352-3026(20)30354-9.
  31. Durie B.G.M., Hoering A., Abidi M.H., Rajkumar S.V., Epstein J., Kahanic S.P., et al. Bortezomib with Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone Alone in Patients with Newly Diagnosed Myeloma Without Intent for Immediate Autologous Stem-Cell Transplant (SWOG S0777): a Randomised, Open-Label, Phase 3 Trial. The Lancet. 2017;389;10068:519–527. doi: 10.1016/S0140-6736(16)31594-X.
  32. Mateos M.V., Dimopoulos M.A., Cavo M., Suzuki K., Jakubowiak A., Knop S., et al. Daratumumab Plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma. N Engl J Med. 2018;378;6:518–528. doi: 10.1056/NEJMoa1714678
  33. Facon T., Venner C.P., Bahlis N.J., Offner F., White D.J., Karlin L., et al. Oral Ixazomib, Lenalidomide, and Dexamethasone for Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma. Blood. 2021;137;26:3616–3628. doi: 10.1182/blood.2020008787.
  34. Kumar S.K., Jacobus S.J., Cohen A.D., Weiss M., Callander N., Singh A.K., et al. Carfilzomib or Bortezomib in Combination with Lenalidomide and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma without Intention for Immediate Autologous Stem-Cell Transplantation (ENDURANCE): a Multicentre, Open-Label, Phase 3, Randomised, Controlled Trial. Lancet Oncol. 2020;21;10:1317–1330. doi: 10.1016/S1470-2045(20)30452-6
  35. Facon T., Kumar S., Plesner T., Orlowski R.Z., Moreau P., Bahlis N., et al. Daratumumab Plus Lenalidomide and Dexamethasone for Untreated Myeloma. N Engl J Med. 2019;380;22:2104-2115. doi: 10.1056/NEJMoa1817249
  36. Attal M., Lauwers-Cances V., Hulin C., Leleu X., Caillot D., Escoffre M., et al. Lenalidomide, Bortezomib and Dexamethasone with Transplantation for Myeloma. N Engl J Med. 2017;376;14:1311–1320. doi: 10.1056/NEJMoa1611750.
  37. Perrot A., Lauwers-Cances V., Corre J., Robillard N., Hulin C., Chretien M.L., Dejoie T., Maheo S., Stoppa A.M., Pegourie B., Karlin L., Garderet L., Arnulf B., Doyen C., Meuleman N., Royer B., Eveillard J.R., Benboubker L., Dib M., Decaux O., Jaccard A., Belhadj K., Brechignac S., Kolb B., Fohrer C., Mohty M., Macro M., Richardson P.G., Carlton V., Moorhead M., Willis T., Faham M., Anderson K.C., Harousseau J.L., Leleu X., Facon T., Moreau P., Attal M., Avet-Loiseau H., Munshi N. Minimal Residual Disease Negativity Using Deep Sequencing is a Major Prognostic Factor in Multiple Myeloma. Blood. 2018 Dec 6;132;23:2456-2464. doi: 10.1182/blood-2018-06-858613. Epub 2018 Sep 24. PMID: 30249784; PMCID: PMC6284215.
  38. Voorhees P.M., Kaufman J.L., Laubach J., Sborov D.W., Reeves B., Rodriguez C., Chari A., Silbermann R., Costa L.J., Anderson L.D. Jr., Nathwani N., Shah N., Efebera Y.A., Holstein S.A., Costello C., Jakubowiak A., Wildes T.M., Orlowski R.Z., Shain K.H., Cowan A.J., Murphy S., Lutska Y., Pei H., Ukropec J., Vermeulen J., de Boer C., Hoehn D., Lin T.S., Richardson P.G. Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone for Transplant-Eligible Newly Diagnosed Multiple Myeloma: the Griffin trial. Blood. 2020 Aug 20;136;8:936-945. doi: 10.1182/blood.2020005288. PMID: 32325490; PMCID: PMC7441167.
  39. Kaiser M.F., Hall A., Walker K., De Tute R., Roberts S., Ingleson E., et al. Depth of Response and Minimal Residual Disease Status in Ultra High-Risk Multiple Myeloma and Plasma Cell Leukemia Treated with Daratumumab, Bortezomib, Lenalidomide, Cyclophosphamide and Dexamethasone (Dara-CVRd): Results of the UK Optimum/MUKnine Trial. J Clin Oncol. 2021; 39;15_suppl:8001. doi: 10.1200/JCO.2021.39.15_suppl.8001.
  40. Rosiñol L., Oriol A., Rios R., Sureda A., Blanchard M.J., Hernández M.T., et al. Bortezomib, Lenalidomide, and Dexamethasone as Induction Therapy Prior to Autologous Transplant in Multiple Myeloma. Blood. 2019;134;16:1337–1345. doi: 10.1182/blood.2019000241
  41. Costa L.J., Chhabra S., Medvedova E., Dholaria B.R., Schmidt T.M., Godby K.N., et al. Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone with Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma. J Clin Oncol. 2021;84:743. doi: 10.1200/JCO.21.01935.

Conflict of interest. The authors declare no conflict of interest.
Financing. The study had no sponsorship. Участие авторов.
Contribution. Article was prepared with equal participation of the authors.
Article received: 19.11.2024. Accepted for publication: 21.11.2024

© 2025 Scientific journal - "Clinical Bulletin of the FMBС im. A.I. Burnasyan"
Scroll to Top